their functions and regulations will provide new insight and important implications in the development of new therapeutics of GBM and other cancers.
results the expression levels of let-7 mirnAs are not reduced in GbM
We first analyzed the expression level of 21 mature miRNA of let-7 family members in GBM as compared to normal brain tissues using the microarray data from 11 independent groups [27] [28] [29] [30] [31] [32] [33] [34] [35] . Results from ten groups indicated that let-7 miRNA levels are not significantly changed in GBM, and one group showed a modest downregulation of only 3 miRNAs, let-7d, let-7f and let-7g (Supplementary Table S1 ).
Next, we compared the expression level of precursor miRNA of let-7 family members in HCC/normal liver tissues and GBM/normal brain tissues. As shown in Table 1 (data from Pablo Landgraf. et al [5] ), in 147 human cells and tissues, both the MC-let-7a-1~let-7d and the let-7 family precursors are significantly down-regulated (more than 10-fold reduction) in HCC. Surprisingly, these precursors are slightly up-regulated (less than 2-fold elevation) in GBM. The miR-21, miR-23a, miR-210 and miR-139, miR-128 and miR-181 are listed as controls to shown that the deep sequence data (NGS) are consistent with the published results [27, [35] [36] [37] [38] [39] . The unbiased datamining results suggest that MC-let-7a-1~let-7d is not downregulated in GBM, in sharp contrast to its expression pattern in HCC. Consistent with the published reports, high level of MYC onco-protein expression in GBM was observed by immune-histochemical staining assays using The Human Protein Atlas database [40] ( Figure 1A , left panel). Moreover, we also analyzed the expression of MYC in a large number of clinical glioblastoma specimens (n = 495) in The Cancer Genome Atlas (TCGA) glioblastoma database. Results indicated that MYC expression is significantly elevated in all glioblastoma subtypes relative to normal human cerebrum ( Figure 1A , right panel).
To further confirm these findings, we carried out gene-expression analyses of MC-let-7a-1~let-7d and MYC in an independent gene-expression cohort including 81 GBM tissues and 23 normal brain tissues according to GEO Profile (GSE4290). The GPL570 microarray platform provides probes to detect the expression of let-7d host gene (MC-let-7a-1~let-7d). As shown in Figure 1B , while MYC level was significantly up-regulated 2.5-fold (p < 0.0001), the expression of MC-let-7a-1~let-7d was not significantly changed (1.13 fold, p = 0.13).
We further examined the expression of pri-let-7a-1, pri-let-7f-1, pri-let-7d and MYC in three human GBM cell lines from high-grade tumors (U-373 MG, U-87 MG, and U-251 MG), one low-grade glioma (SW-1088), and www.impactjournals.com/oncotarget a malignant neuroectodermal tumor (PFSK-1) by RealTime PCR assays. Consistently, the pri-let-7a-1, pri-let7f-1, and pri-let-7d levels were not significantly changed as compared to normal brain tissue (NBT, Figure 1C ), while MYC level was significantly elevated in all cell lines ( Figure 1D ).
characterization of the promoter of Mc-let-7a-1~let-7d cluster in GbM u87 and u251 cells
Previously, we have characterized the MC-let-7a-1~let-7d promoter in HCC [15] . Here, we charaterize the promoter and transcription start site(s) of MC-let-7a-1~let-7 in GBM U87 and U251 cells by 5' Rapid Amplification of cDNA Ends (5'RACE) assays using total RNA as templates, gene-specific primers GSP1-1 for the synthesis of first strand cDNA, and GSP2-1 and GSP2-2 for nested PCR (Figure 2A) . A ~700 bp product was amplified ( Figure 2B ) and cloned. Sequence analysis of twenty 5'RACE products (10 products for each cells) revealed that the TSSs of MClet-7a-1~let-7d in U87 and U251 are located about 28 bp and 40 bp, respectively, downstream of the TSSs found in HepG2 cells ( Figure 2C ). These results suggested that MClet-7a-1~let-7d uses similar promoter regions in HCC and GBM with different TSSs.
In addition, we compared the promoter activity of the highly conserved region around the TSSs. Our results showed that the promoter regions of MC-let-7a-1~let-7d exhibited similar property in GBM (U87 cells) as compared to that of the liver L02 cells. As shown in Figure 2D , truncation analysis revealed that promoter (−540bp to +1bp) exhibited maximal activity. In addition, the presence of a suppression element from +1317 to +1 and an activator from −540 to −227 were detected in both U87 cells and L02 cells.
MYc failed to inhibit the expression of human
Mc-let-7a-1~let-7d micrornA cluster in GbM cells.
To investigate whether MYC differentially regulates the transcription of MC-let-7a-1~let-7d in HCC and GBM, we over-expressed MYC in HepG2, L02, U87, and U251 cells. As expected, forced expression of MYC significantly down-regulated MC-let-7a-1~let-7d expression only in L02 and HepG2 cells (Figure3A), but not in U87 and U251 cells ( Figure 3B ).
We further validated these findings in HCC-and GBM-patient samples. Pearson's correlation and Linear Regression analysis were employed using data from GSE55092 (HCC, tumor = 49, non-tumor = 91) and GSE4290 (GBM, tumor = 81, non-tumor = 23). The converse relationship of MC-let-7a-1~let-7d and MYC was only observed in HCC samples ( Figure 3C MYc failed to down-regulate the promoter activity of Mc-let-7a-1~let-7d cluster in GbM
Our previous study showed that MYC downregulates the transcription of MC-let-7a-1~let-7d in HCC, and identified two functional MYC binding E-box elements (E-box 2, 3) [15] . We showed that over-expression of MYC significantly reduced the expression of MC-let-7a-1~let-7d primary transcript through the non-canonical E-box 3, in L02 and HepG2 cells. To examine the transcriptional regulation in GBM, we first determined the effect of MYC in MC-let-7a-1~let-7d promoter PPR-10 which only contains canonical E-box 2 ( Figure 4A ). Our results indicated that over-expression of MYC activated luciferase activity of PPR-10 in all the four cells lines HepG2, L02, U87, and U251, suggesting the similar function of basal activity of canonical E-box 2 ( Figure 4B ). Furthermore, over-expression of MYC significantly repressed the activity of PPR-3 which contains both canonical E-box 2 and noncanonical E-box 3 in HepG2 and L02 cells, however, it could not change the activity of PPR-3 in GBM U87 and U251 cells ( Figure 4C ). These results suggested a defective function of the non-canonical E-box 3 in GBM.
defective MYc and e-box 3 binding in GbM
We determined the binding ability of MYC to E-box 3 in GBM U87 and U251 cells by ChIP assays to quantify the MYC binding quantum on E-box 2 and Oncotarget 56270 www.impactjournals.com/oncotarget E-box 3. The results from Real-time PCR experiments were summarized and shown as relative binding (MYC ChIP relative to input ChIP). As shown in Figure 4D , strong MYC binding was observed in E-box 2 but not in E-box 3, suggesting the absence of MYC and E-box 3 binding in GBM.
Furthermore, EMSA assays and super-shift analysis were performed to confirm the loss of MYC binding to E-box 3 in U87 and U251 cells. Competition assays were conducted by adding 100-fold molar unlabeled E-boxes. As shown in Figure 4E , E-box 3 showed shift bands by adding nuclear extract from U87 and U251 cells. However, supershift bands were not observed by adding nuclear extract form U87 and U251 with MYC antibody. These results confirmed that MYC onco-protein could not bind to E-box 3 in GBM. Pearson correlation is calculated to measure the strength of a linear association between the expressions of two genes. R-square is the coefficient of linear regression which measures the linearity between the expressions of two genes. *p < 0.05; **p < 0.01. Oncotarget 56272 www.impactjournals.com/oncotarget dIscussIon MYC is an evolutionarily conserved E-box binding transcription factor. It is pathologically activated in many human malignancies [41] . The expression of MYC is important in cell signaling pathways such as cell growth/ proliferation, metabolism and apoptosis [42] . It has been reported that MYC expression is elevated in almost all cancers including both HCC and GBM [18, 41] . As compared to a nearly undetectable level in normal brain tissues, MYC is expressed in 80.6% of primary glioblastoma samples [43, 44] , and in 73% of astrocytomas [45] . The wide spread repression of miRNAs including let-7 by MYC and its contribution to tumorigenesis has also been clearly demonstrated [46] .
Previously, we reported that MYC inhibited the transcription of MC-let-7a-1~let-7d in HCC [15] . We proposed that MYC exhibited dual functions in the transcriptional regulation of MC-let-7a-1~let-7d. As shown in Figure 5 , in non-cancerous L02 cells with a low level of MYC, MYC dimerizes with Max and bind to the canonical E-box 2 to activate and maintain the basal expression level . The E-box 2 region was significantly enriched, whereas the E-box 3 region was not enriched both in U87 and U251. (e) EMSA and supershift assay analysis of MYC binding to E-box 3 in U87 and U251. Competition assays were performed adding to 100-fold molar unlabeled E-boxes. Shift bands were observed by adding nuclear extract form both U87 and U251, whereas supershift bands was not observed by adding nuclear extract form U87 and U251 with MYC antibody.
Oncotarget 56273 www.impactjournals.com/oncotarget of let-7. However, in cancerous HepG2 cells with elevated MYC, the extra MYC binds to the non-canonical E-box 3 to suppress the transcription of MC-let-7a-1~let-7d. These mechanisms enable cancer cells to maintain a high level of MYC and a low level of let-7 miRNAs simultaneously in HCC.
In present study, we reported that MC-let-7a-1~let-7d is not down-regulated in GBM due to the loss of MYC and E-box 3 binding. The detailed molecular mechanism for this defect is not known at present. One explaination is that the binding of MYC to E-box 3 requires additional unknown intermediary trans-acting factors that are defective or absent in GBM.
In the promoter truncation assay, we found that the −540 bp to +1bp region of MC-let-7a-1~let-7d promoter exhibited maximal promoter activity, while longer promoters PPR-1~4 showed decreased promoter activity. These results indicated the presence of suppression elements downstream of the transcription initiation site. Indeed, our study showed that MYC also acts as a transcription suppressor by binding to the non-canonical binding site E-box 3 located downstream of TSSs. However, it is not clear whether and how MYC bind to the non-canonical DNA sequence to suppress the promoter activity. Results from our study inferred that MYC might not bind to E-box3 directly, but is recruited to the promoter by yet to be identified factor, which is present in HCC, but either defective or absent in GBM.
Identification and characterization of this MYC-E-box3
It has been reported that the expression of let-7 family members are increased during neural differentiation and let-7 members play important roles in neural stem cell proliferation and differentiation [47] [48] [49] [50] . Lee et al showed that over-expression of let-7 miRNAs could reduce the proliferation and migration of GBM cells, as well as the tumor size in nude mice xenograft transplanted GBM [51] . Forced expression of let-7 miRNA reduced expression of pan-RAS, N-RAS, and K-RAS [51] , suggesting that let-7 played important tumor suppressor roles in GBM. Our in silico and wet-lab findings suggest that let-7 escapes MYC inhibition in GBM. It is not known whether the co-existence of high levels of onco-MYC and tumor suppressor-let-7 had any impact in the carcinogenesis of brain tumors. As let-7 miRNAs could inhibit the expression of MYC, and how MYC escapes inhibition by let-7 in GBM is also not understood. The existence of recently discovered competing endogenous RNA (ceRNA), and whether they play a role requires further investigations [52, 53] .
The present study provided a model to explain the the differential transcriptional regulation of tumor suppressor let-7 by oncogene MYC in glioblastoma and hepatocellular carcinoma. These results suggest a potential molecular mechanism for understanding the complexity of molecular regulatory network. The potential implications in cancer treatment warrant further investigations. , human primitive neuroectodermal PFSK-1 cells, and human low-grade glioma SW-1088 cells were also obtained from ATCC. All these cell lines were cultured in Dulbecco's modified eagles medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, Gibco) at 37°C in a humidified atmosphere with 5% CO 2 as our previous report [15, 54] .
tissue samples
Three adjacent normal human brain tissue (NBT) specimens were collected from 3 male GBM patients with 23-, 34-and 35-year-old respectively at Sun Yat-sen University Cancer Center. Patients' consent and approval from Sun Yatsen University Cancer Center Institute Research Ethics Committee were obtained for the use of these clinical materials. For each sample, total RNA were purified by using AllPrep Mini Kit (Qiagen,Cat number 80004) according to the manufactures' instructions.
Genomic dnA extraction, rnA extraction, cdnA synthesis and real-time Pcr
For genomic DNA extraction, total cell genomic DNA was extracted using the DNeasy Blood & Tissue (Qiagen), following the manufacturer's instructions. For RNA extraction, total RNA was extracted using Trizol (Invitrogen), according to the manufacturer's instructions. For cDNA synthesis, 2 μg total RNA was reverse transcribed by the SuperScript™ III First-Strand Synthesis System (Invitrogen) after DNase I treatment (Invitrogen). Quantitive Real-Time polymerase chain reaction (qRT-PCR) was subsequently performed in triplicate with a 1:10 dilution of the resultant cDNA using the Brilliant Brilliant ® II SYBR ® Green QPCR Master Mix (Stratagene) on the Applied Biosystems 7500 RealTime PCR System Instrument (Applied Biosystems). All mRNA quantification data were normalized to GAPDH. Ct-value for each sample was calculated with the ΔΔCt-method and results were expressed as 2 -ΔΔCT [55] .
Protein extraction and Western blot analysis
Cells were seeded onto a 6-well plate at a density of 10 6 cells/well. Cells were lysed for 30 min on ice in RIPA lysis buffer (Bioteke) with protease inhibitor cocktail. Protein concentration was determined by Bio-Rad protein assay kit (Bio-Rad). Fifty ug proteins were separated by 12% SDS polyacrylamide gels (SDS-PAGE) and transferred onto PVDF membranes. Membranes were probed with specific antibodies includingMYC (1:2000; Abcam) or β-actin (1:3000; Abcam) respectively. After washing, membranes were incubated with HRP-conjugated secondary antibody (1:5000; Abcam). Membranes were exposed using the enhanced chemiluminescence (ECL) substrate kit (Thermo) and imaged using the ImageQuant™ RT ECL™ system (GE Healthcare). The expression level of β-actin was also determined and served as an internal control.
5′ Rapid Amplification of cDNA Ends (5′ RACE)
The 5′ RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (Invitrogen) was used according to the manufacturer's instructions. Briefly, cDNA was synthesized using the MC-let-7a-1~let-7d Specific Primers GSP1-1 (Supplementary Table S2 ). Primary amplification was carried out with abridged anchor primer (AAP, provided in the kit) and GSP2-1 primer (Supplementary Table S2 ). Nested PCR was performed with abridged universal amplification primer (AUAP, provided in the kit) and GSP2-2 (Supplementary Table S2 ) using TaKaRa LA Taq ® with GC Buffer I (TaKaRa). The 5′RACE PCR products were resolved on 1% agarose gel and stained by EtBr. The bands were excised, cloned into pGL3 Basic Vector (Promega) via restriction endonuclease Mlu I sites and sequenced.
constructions of promoter reporter, and MYc expression plasmids A 1.9 kb MC-let-7a-1~let-7d promoter was amplified by PCR using PrimeSTAR™ HS DNA Polymerase (TaKaRa) and cloned into pGL3 Basic Vector (Promega) between Xho I and Hind III sites using primers PPR-1 as listed in Supplementary Table S2 . This plasmid was named as PPR-1. Subsequent promoter truncations were generated from this template and cloned in a similar manner using the primers in Supplementary Table S2 . To construct MYC expression vector, human MYC open reading frame (ORF) was amplified using MYC primers as indicated in Supplementary Table S2 and inserted into the pcDNA3.1(+) vector (Invitrogen) between Hind III and BamH I sites. The sequence and orientation of all of the inserts were confirmed by sequencing.
luciferase reporter assays
HepG2 cells, L02 cells, U87 cells or U251 cells cells were plated at a density of 50,000 cells per well in a 24-well plate at 24 hrs before transfection. Cells were co-transfected with 250 ng MC-let-7a-1~let-7d promoter/firefly luciferase reporter plasmids and 5 ng pRL-TK Renilla plasmids (Promega) using FuGENE ® HD Transfection Reagent (Promega). For gain and loss-of-function experiments, 750 ng MYC expression plasmids (c-Myc) or its control vectors (pcDNA3.1) were transfected. After 48 h posttransfection, cells were either lysed in Trizol (Invitrogen)
